Vivo Capital, LLC Tarsus Pharmaceuticals, Inc. Transaction History

Vivo Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$19.61 - $39.22 $23.9 Million - $47.8 Million	-1,218,456 Reduced 68.3%	565,550 $20.6 Million
Q4 2023 Feb 06, 2024	SELL	$12.98 - $20.73 $6.21 Million - $9.91 Million	-478,194 Reduced 21.14%	1,784,006 $36.1 Million
Q3 2022 Nov 14, 2022	SELL	$14.08 - $18.5 $706,365 - $928,108	-50,168 Reduced 2.17%	2,262,200 $38.7 Million
Q2 2022 Aug 15, 2022	SELL	$11.08 - $19.08 $7.48 Million - $12.9 Million	-674,963 Reduced 22.59%	2,312,368 $33.8 Million
Q2 2021 Aug 16, 2021	SELL	$27.16 - $38.59 $7 Million - $9.94 Million	-257,704 Reduced 7.94%	2,987,331 $86.6 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $49.62 $62.2 Million - $161 Million	3,245,035 New	3,245,035 $134 Million

173

43.6M

484K

4.1K

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.31B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Vivo Capital, LLC with notifications on news.